Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors

NCT04381650 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT04381650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04381650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors
Lead sponsor
Takeda
Phase
Phase 1/2
Overall status
Completed
Start date
August 17, 2020
Completion date
October 29, 2024
Enrollment
161 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors